chevron_left
Revolutionary gene therapies for sickle cell pose challenges for payers
Casgevy™ and Lyfgenia™ are game-changers for patients with sickle cell disease (SCD). The first FDA-approved cell-based gene therapies for SCD, they come with multimillion-dollar list prices, posing a test for payers – and for the U.S. government’s new voluntary outcomes-based Cell and Gene Therapy Access Model.
This report, featuring proprietary Clarivate data and insights, examines the market access landscape surrounding these therapeutics, including:
- Market share and growth
- Value to price ratio
- Cost and coverage challenges
- Outcomes-based agreements
- Payer coverage versus competitors
- Adverse events
- Company-sponsored patient access programs
- Physician perceptions and barriers to prescribing
